Hieff Trans®脂质体核酸转染试剂是一种多用途的脂质体转染试剂，适用于DNA、RNA和寡核苷酸的转染，对大多数真核细胞具有很高的转染效率。其独特的配方使其可直接加入培养基中，血清的存在不会影响转染效率，这样可以减少去除血清对细胞的损伤。转染后不需要除去核酸-Hieff Trans®复合物或更换新鲜培养基，也可在4～6小时后除去。
Hieff Trans®脂质体核酸转染试剂以无菌的液体形式提供。通常情况下对于 24 孔板转染，每次用1.5 μL左右，则1 mL 约可做660 次转染；对于6孔板，每次用6 μL左右，则1 mL约可做160 次转染。
高效性： 可对大多数真核细胞进行转染，并且对于常见细胞系转染效率达90%以上；
低毒性：转染细胞形态良好并表达大量的转染基因蛋白；
操作简便：可以直接将脂质体复合物加入到含血清的培养基中；
多样性：适合瞬时转染和稳定转染试验。
已验证细胞系
冰袋（wet ice）运输。产品2-8ºC保存，一年有效。不可冷冻！
Q：脂质体转染的效率多少，毒性如何？
A：有些细胞如 293T、293FT、Hela 等转染效率基本在85%以上；所有阳离子脂质体转染试剂对细胞都会存在一定的毒性，但是我们公司的转染试剂经过配方优化后其毒性大大降低，且转染效率也有进一步提升。
Q：转染试剂转染后需要换液吗？
A：对于换液可以区分两种情况；1、转染之前如果没有换液应在转染 6 小时左右后换液，以保证细胞生长所需营养，2、如果转染之前如果有换液，可以按照平时等到培养基出现营养不足时换液。
Q：转染试剂转单个质粒和多质粒共转的效率如何？
A:单转效率对于验证过的细胞效率都是很好，可以参考FAQ-验证过的细胞系，对于共转由于要涉及到质粒的混合比例和质粒与转染试剂的添加比例问题，因此具体的效率需要做相应的验证。
Q：转染试剂可以冻存吗？
A:不可以冻存，因为转染试剂是一种脂质体阳离子转染试剂，由于脂质体是不能在低温下冻存，因此转染试剂最好是 4 度储存，保持最好的转染效能。
Q：转染实验过程中是否需要更换成无血清培养基？
A：不需要，我们的转染试剂可以在含血清的介质中进行转染的过程。
Q：转染后需要进行终止反应吗？
A：不需要。脂质体复合物可以稳定存在 6 个小时。如果在进行转染前没有进行细胞换 液，为了保证细胞正常生长所需的营养，需要在 4～6 小时后换用新的培养基。但如果转染之前已进行过换液则在脂质体转染后不需要进行再次换液。
Q：转染试剂毒性相比之前的批次大？
A：40802产品进行的工艺优化，纯度增高，相应的转染效率也随之变高，建议质粒与转染试剂的比例在1:2进行调整，一旦出现细胞死亡的现象，降低转染试剂比列。或者转染6h后进行换液。
Q: 它的大致成分和脂质体粒径，我们可以提供吗？
A: 提供不了粒径取决于客户的核酸和实验条件的 不是一个绝对值的。
Q: 如果是悬浮细胞的话，可以不换直接将核酸转染试剂复合物添也，加到培养基中吗?
A: 做悬浮细胞转染的时候，会在前一天进行细胞传代，比如用T25传代，转染当天，根据使用的孔板类型，细胞计数后，吸取对应细胞量加入孔板中，然后补新鲜培养基至一定体积就可以，这个时候就可以直接把转染复合物加进去。
[1] Liu R, Yang J, Yao J, et al. Optogenetic control of RNA function and metabolism using engineered light-switchable RNA-binding proteins. Nat Biotechnol. 2022;40(5):779-786. doi:10.1038/s41587-021-01112-1(IF:54.908)
[2] Fan Y, Wang J, Jin W, et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. Mol Cancer. 2021;20(1):25. Published 2021 Feb 2. doi:10.1186/s12943-021-01321-x(IF:27.401)
[3] Tao R, Zhao Y, Chu H, et al. Genetically encoded fluorescent sensors reveal dynamic regulation of NADPH metabolism. Nat Methods. 2017;14(7):720-728. doi:10.1038/nmeth.4306(IF:25.062)
[4] Zhang Q, He X, Yao S, et al. Ablation of Mto1 in zebrafish exhibited hypertrophic cardiomyopathy manifested by mitochondrion RNA maturation deficiency. Nucleic Acids Res. 2021;49(8):4689-4704. doi:10.1093/nar/gkab228(IF:16.971)
[5] Liang Y, Lu Q, Li W, et al. Reactivation of tumour suppressor in breast cancer by enhancer switching through NamiRNA network. Nucleic Acids Res. 2021;49(15):8556-8572. doi:10.1093/nar/gkab626(IF:16.971)
[6] Wu S, Cao R, Tao B, et al. Pyruvate Facilitates FACT-Mediated γH2AX Loading to Chromatin and Promotes the Radiation Resistance of Glioblastoma. Adv Sci (Weinh). 2022;9(8):e2104055. doi:10.1002/advs.202104055(IF:16.806)
[7] Luo Q, Wu X, Zhao P, et al. OTUD1 Activates Caspase-Independent and Caspase-Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation. Adv Sci (Weinh). 2021;8(8):2002874. Published 2021 Feb 8. doi:10.1002/advs.202002874(IF:16.806)
[8] Chen S, Cao X, Zhang J, Wu W, Zhang B, Zhao F. circVAMP3 Drives CAPRIN1 Phase Separation and Inhibits Hepatocellular Carcinoma by Suppressing c-Myc Translation. Adv Sci (Weinh). 2022;9(8):e2103817. doi:10.1002/advs.202103817(IF:16.806)
[9] Yan JM, Zhang WK, Yan LN, Jiao YJ, Zhou CM, Yu XJ. Bunyavirus SFTSV exploits autophagic flux for viral assembly and egress. Autophagy. 2022;18(7):1599-1612. doi:10.1080/15548627.2021.1994296(IF:16.016)
[10] Xu X, Zhang J, Tian Y, et al. CircRNA inhibits DNA damage repair by interacting with host gene. Mol Cancer. 2020;19(1):128. Published 2020 Aug 24. doi:10.1186/s12943-020-01246-x(IF:15.302)
[11] Huang K, Chen X, Li C, et al. Structure-based investigation of fluorogenic Pepper aptamer. Nat Chem Biol. 2021;17(12):1289-1295. doi:10.1038/s41589-021-00884-6(IF:15.040)
[12] Li T, Chen X, Qian Y, et al. A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice. Nat Commun. 2021;12(1):615. Published 2021 Jan 27. doi:10.1038/s41467-021-20913-1(IF:14.919)
[13] Liu Z, Chen S, Lai L, Li Z. Inhibition of base editors with anti-deaminases derived from viruses. Nat Commun. 2022;13(1):597. Published 2022 Feb 1. doi:10.1038/s41467-022-28300-0(IF:14.919)
[14] Wu C, Wang C, Zheng J, et al. Vacuolization in Cytoplasm and Cell Membrane Permeability Enhancement Triggered by Micrometer-Sized Graphene Oxide. ACS Nano. 2015;9(8):7913-7924. doi:10.1021/acsnano.5b01685(IF:12.881)
[15] Zou Y, Wang A, Shi M, et al. Analysis of redox landscapes and dynamics in living cells and in vivo using genetically encoded fluorescent sensors. Nat Protoc. 2018;13(10):2362-2386. doi:10.1038/s41596-018-0042-5(IF:12.423)
[16] Sun X, Peng X, Cao Y, Zhou Y, Sun Y. ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling. Nat Commun. 2020;11(1):2984. Published 2020 Jun 12. doi:10.1038/s41467-020-16799-0(IF:12.121)
[17] Song L, Liu Z, Hu HH, et al. Proto-oncogene Src links lipogenesis via lipin-1 to breast cancer malignancy. Nat Commun. 2020;11(1):5842. Published 2020 Nov 17. doi:10.1038/s41467-020-19694-w(IF:12.121)
[18] Shui S, Zhao Z, Wang H, Conrad M, Liu G. Non-enzymatic lipid peroxidation initiated by photodynamic therapy drives a distinct ferroptosis-like cell death pathway. Redox Biol. 2021;45:102056. doi:10.1016/j.redox.2021.102056(IF:11.799)
[19] Du L, Xie Y, Zheng K, et al. Oxidative stress transforms 3CLpro into an insoluble and more active form to promote SARS-CoV-2 replication [published online ahead of print, 2021 Nov 26]. Redox Biol. 2021;48:102199. doi:10.1016/j.redox.2021.102199(IF:11.799)
[20] Cen M, Ouyang W, Zhang W, et al. MitoQ protects against hyperpermeability of endothelium barrier in acute lung injury via a Nrf2-dependent mechanism. Redox Biol. 2021;41:101936. doi:10.1016/j.redox.2021.101936(IF:11.799)
[21] Sun X, Peng X, Cao Y, Zhou Y, Sun Y. ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling. Nat Commun. 2020;11(1):2984. Published 2020 Jun 12. doi:10.1038/s41467-020-16799-0(IF:11.614)
[22] Liu W, Zhan Z, Zhang M, et al. KAT6A, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1. Theranostics. 2021;11(13):6278-6292. Published 2021 Apr 15. doi:10.7150/thno.57455(IF:11.556)
[23] Hao Q, Li J, Zhang Q, et al. Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma. Clin Transl Med. 2021;11(8):e500. doi:10.1002/ctm2.500(IF:11.492)
[24] Zhang Y, Yu X, Sun R, et al. Splicing factor arginine/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication. Clin Transl Med. 2022;12(2):e684. doi:10.1002/ctm2.684(IF:11.492)
[25] Liu Z, Chen S, Xie W, et al. Versatile and efficient in vivo genome editing with compact Streptococcus pasteurianus Cas9. Mol Ther. 2022;30(1):256-267. doi:10.1016/j.ymthe.2021.06.013(IF:11.454)
[26] Tang X, Deng Z, Ding P, et al. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J Exp Clin Cancer Res. 2022;41(1):85. Published 2022 Mar 8. doi:10.1186/s13046-022-02276-7(IF:11.161)
[27] Gu C, Wang Y, Zhang L, et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 2022;41(1):11. Published 2022 Jan 6. doi:10.1186/s13046-021-02220-1(IF:11.161)
[28] Chen P, Zhou J, Wan Y, et al. A Cas12a ortholog with stringent PAM recognition followed by low off-target editing rates for genome editing. Genome Biol. 2020;21(1):78. Published 2020 Mar 25. doi:10.1186/s13059-020-01989-2(IF:10.806)
相关产品
